240 related articles for article (PubMed ID: 21324354)
21. Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.
Qian F; Huang J; Hussain MA
J Pharm Sci; 2010 Jul; 99(7):2941-7. PubMed ID: 20127825
[TBL] [Abstract][Full Text] [Related]
22. Phase transformation considerations during process development and manufacture of solid oral dosage forms.
Zhang GG; Law D; Schmitt EA; Qiu Y
Adv Drug Deliv Rev; 2004 Feb; 56(3):371-90. PubMed ID: 14962587
[TBL] [Abstract][Full Text] [Related]
23. Modeling and prediction of cocrystal phase diagrams.
Ainouz A; Authelin JR; Billot P; Lieberman H
Int J Pharm; 2009 Jun; 374(1-2):82-9. PubMed ID: 19446763
[TBL] [Abstract][Full Text] [Related]
24. Barrier coated drug layered particles for enhanced performance of amorphous solid dispersion dosage form.
Puri V; Dantuluri AK; Bansal AK
J Pharm Sci; 2012 Jan; 101(1):342-53. PubMed ID: 21935949
[TBL] [Abstract][Full Text] [Related]
25. The glass transition temperatures of amorphous trehalose-water mixtures and the mobility of water: an experimental and in silico study.
Simperler A; Kornherr A; Chopra R; Jones W; Motherwell WD; Zifferer G
Carbohydr Res; 2007 Aug; 342(11):1470-9. PubMed ID: 17511976
[TBL] [Abstract][Full Text] [Related]
26. Solution calorimetry as an alternative approach for dissolution testing of nanosuspensions.
Kayaert P; Li B; Jimidar I; Rombaut P; Ahssini F; Van den Mooter G
Eur J Pharm Biopharm; 2010 Nov; 76(3):507-13. PubMed ID: 20887787
[TBL] [Abstract][Full Text] [Related]
27. Crystallization rate of amorphous nifedipine analogues unrelated to the glass transition temperature.
Miyazaki T; Yoshioka S; Aso Y; Kawanishi T
Int J Pharm; 2007 May; 336(1):191-5. PubMed ID: 17184940
[TBL] [Abstract][Full Text] [Related]
28. Predicting the diffusion coefficient of water vapor through glassy HPMC films at different environmental conditions using the free volume additivity approach.
Laksmana FL; Hartman Kok PJ; Vromans H; Van der Voort Maarschalk K
Eur J Pharm Sci; 2009 Jul; 37(5):545-54. PubMed ID: 19409985
[TBL] [Abstract][Full Text] [Related]
29. Molecular Dynamics, Recrystallization Behavior, and Water Solubility of the Amorphous Anticancer Agent Bicalutamide and Its Polyvinylpyrrolidone Mixtures.
Szczurek J; Rams-Baron M; Knapik-Kowalczuk J; Antosik A; Szafraniec J; Jamróz W; Dulski M; Jachowicz R; Paluch M
Mol Pharm; 2017 Apr; 14(4):1071-1081. PubMed ID: 28231007
[TBL] [Abstract][Full Text] [Related]
30. Crystal growth formation in melt extrudates.
Bruce C; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
Int J Pharm; 2007 Aug; 341(1-2):162-72. PubMed ID: 17524578
[TBL] [Abstract][Full Text] [Related]
31. Solid state NMR perspective of drug-polymer solid solutions: a model system based on poly(ethylene oxide).
Schachter DM; Xiong J; Tirol GC
Int J Pharm; 2004 Aug; 281(1-2):89-101. PubMed ID: 15288346
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches.
Fakes MG; Vakkalagadda BJ; Qian F; Desikan S; Gandhi RB; Lai C; Hsieh A; Franchini MK; Toale H; Brown J
Int J Pharm; 2009 Mar; 370(1-2):167-74. PubMed ID: 19100319
[TBL] [Abstract][Full Text] [Related]
33. The stability of solid dispersions of felodipine in polyvinylpyrrolidone characterized by nanothermal analysis.
Zhang J; Bunker M; Parker A; Madden-Smith CE; Patel N; Roberts CJ
Int J Pharm; 2011 Jul; 414(1-2):210-7. PubMed ID: 21627985
[TBL] [Abstract][Full Text] [Related]
34. Glass Transition Dynamics and Physical Stability of Amorphous Griseofulvin in Binary Mixtures with Low-
Tu W; Knapik-Kowalczuk J; Chmiel K; Paluch M
Mol Pharm; 2019 Aug; 16(8):3626-3635. PubMed ID: 31287704
[TBL] [Abstract][Full Text] [Related]
35. Adsorption of pharmaceutical excipients onto microcrystals of siramesine hydrochloride: effects on physicochemical properties.
Zimmermann A; Millqvist-Fureby A; Elema MR; Hansen T; Müllertz A; Hovgaard L
Eur J Pharm Biopharm; 2009 Jan; 71(1):109-16. PubMed ID: 18619536
[TBL] [Abstract][Full Text] [Related]
36. Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water-soluble drugs.
Overhoff KA; Engstrom JD; Chen B; Scherzer BD; Milner TE; Johnston KP; Williams RO
Eur J Pharm Biopharm; 2007 Jan; 65(1):57-67. PubMed ID: 16987642
[TBL] [Abstract][Full Text] [Related]
37. Amorphous-Amorphous Phase Separation in API/Polymer Formulations.
Luebbert C; Huxoll F; Sadowski G
Molecules; 2017 Feb; 22(2):. PubMed ID: 28212300
[TBL] [Abstract][Full Text] [Related]
38. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
[TBL] [Abstract][Full Text] [Related]
39. Choosing Appropriate Solvents for ASD Preparation.
Luebbert C; Real D; Sadowski G
Mol Pharm; 2018 Nov; 15(11):5397-5409. PubMed ID: 30335401
[TBL] [Abstract][Full Text] [Related]
40. Liquisolid systems and aspects influencing their research and development.
Vraníková B; Gajdziok J
Acta Pharm; 2013 Dec; 63(4):447-65. PubMed ID: 24451071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
